CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo. (2020)
Attributed to:
BAG-1: A novel strategy for targeting the androgen receptor splice variants in castrate resistant prostate cancer.
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1172/jci131133
PubMed Identifier: 32250342
Publication URI: http://europepmc.org/abstract/MED/32250342
Type: Journal Article/Review
Volume: 130
Parent Publication: The Journal of clinical investigation
Issue: 5
ISSN: 0021-9738